Search and analyze individual stocks with comprehensive metrics
AstraZeneca Pharma India Limited
Fundamental Score
AstraZeneca Pharma India Limited Share Price & Market Analysis
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of ASTRAZEN across key market metrics for learning purposes.
Positive Indicators
12 factors identified
Strong Return on Equity (23.63%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (33.40%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Robust Profit Growth (60.14%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Strong Revenue Growth (35.81%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.
Consistent Growth Track Record (15.59% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model and market opportunity execution over time.
Excellent EPS Growth (19.45% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential and effective capital allocation over extended periods.
Strong Profit Growth Track Record (19.45% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.
Conservative Debt Levels (D/E: 0.05)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (139.07x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Strong Cash Generation (₹329.01 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (75.00%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
4 factors identified
Premium Valuation Risk (P/E: 104.30x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.
Limited Institutional Interest (FII+DII: 7.58%)
Observation: Low institutional participation may affect liquidity and visibility.
Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Very High P/E Ratio
Observation: Significant overvaluation risk present.
Analysis: Extremely high P/E ratios indicate potential bubble territory and high downside risk.
📊 Educational Market Overview
Disclaimer: The ratings and scores are generated algorithmically from publicly available market data and are provided for educational and informational purposes only. They do not constitute investment advice, recommendation, or solicitation to buy/sell any securities.
Loading Peer Comparison
Finding companies in the Pharmaceuticals sector...
Financial Statements
Comprehensive financial data for AstraZeneca Pharma India Limited
About ASTRAZEN
Company Details
Market Information
Performance
ASTRAZEN Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of ASTRAZEN?
ASTRAZEN is currently trading at ₹9222.50 with a gain of 0.00% today. The current market price (CMP) represents the last traded price of ASTRAZEN shares on the stock exchange. This price fluctuates throughout trading hours based on supply and demand. You can track real-time price movements, percentage changes, and trading volume in the header section.
What is the P/E ratio of ASTRAZEN and what does it mean?
ASTRAZEN has a P/E ratio of 104.30x compared to the industry average of 33.97x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹104 for every ₹1 of annual earnings. This is higher than the industry average, suggesting either growth premium or potential overvaluation.
How is ASTRAZEN performing according to Bull Run's analysis?
ASTRAZEN has a Bull Run fundamental score of 75.4/100, which indicates strong fundamentals and excellent investment quality. This comprehensive rating is based on 15+ financial parameters including profitability (ROE: 23.63%), growth metrics, valuation ratios, and financial health indicators. The score updates quarterly with new financial data and helps you quickly assess overall investment quality.
What sector and industry does ASTRAZEN belong to?
ASTRAZEN operates in the Pharmaceuticals & Biotechnology industry. This sector classification helps understand the broader economic trends, regulatory framework, and competitive landscape affecting AstraZeneca Pharma India Limited. Companies in this industry typically face similar market dynamics, cyclical patterns, and macroeconomic factors. Understanding the industry context is crucial for peer comparison and assessing how sector-specific trends might impact the stock's performance.
What is Return on Equity (ROE) and why is it important for ASTRAZEN?
ASTRAZEN has an ROE of 23.63%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently AstraZeneca Pharma India Limited generates profits from shareholders' equity. An ROE of 24% means the company generates ₹24 profit for every ₹100 of shareholders' equity. This metric is crucial for assessing management's ability to create value for shareholders.
How is ASTRAZEN's debt-to-equity ratio and what does it indicate?
ASTRAZEN has a debt-to-equity ratio of 0.05, which indicates conservative financing with low financial risk. This means the company has ₹5 of debt for every ₹100 of equity. This conservative approach provides financial stability but may limit growth potential.
What is ASTRAZEN's dividend yield and is it a good dividend stock?
ASTRAZEN offers a dividend yield of 0.36%, which means you receive ₹0.36 annual dividend for every ₹100 invested. The focus appears to be more on growth rather than dividend income. Dividend yield is calculated as annual dividend per share ÷ current share price × 100. Evaluate dividend consistency over 5+ years and free cash flow coverage for sustainability.
How has ASTRAZEN grown over the past 5 years?
ASTRAZEN has achieved 5-year growth rates of: Sales Growth 15.59%, Profit Growth 19.45%, and EPS Growth 19.45%. This consistent double-digit growth indicates a strong business model and competitive positioning. Sales growth indicates market expansion, profit growth shows operational efficiency, and EPS growth directly impacts share price appreciation potential.
What is the promoter holding in ASTRAZEN and why does it matter?
Promoters hold 75.00% of ASTRAZEN shares, with 0.00% of promoter shares pledged. This high promoter holding indicates strong management confidence and alignment with shareholders. Low pledging indicates financial stability of promoters. Recent change in promoter holding: 0.00%.
How does ASTRAZEN compare with its industry peers?
ASTRAZEN trades at P/E 104.30x vs industry average 33.97x, with ROE of 23.63% and ROCE of 33.40%. The stock trades at a premium to industry average, which may be justified by superior fundamentals. Peer comparison helps identify whether ASTRAZEN is outperforming its competitive set in profitability, growth, and valuation metrics.
What is ASTRAZEN's market capitalization and what category does it fall into?
ASTRAZEN has a market capitalization of ₹22054 crores, making it a Large-cap stock. Large-cap stocks offer stability and liquidity but typically slower growth. Market cap is calculated as current share price × total outstanding shares, representing the company's total market value.
What are the key financial ratios to consider for ASTRAZEN?
Key ratios for ASTRAZEN: ROE 23.63% (Excellent), ROCE 33.40%, P/E 104.30x, Debt-to-Equity 0.05, Interest Coverage 139.07x. These ratios help assess profitability (ROE, ROCE), valuation (P/E), financial health (D/E, Interest Coverage), and overall investment quality. Compare these with industry medians and historical trends for meaningful analysis.
How volatile is ASTRAZEN stock and what is its beta?
ASTRAZEN has a beta of N/A, which means it is less volatile than the market and offers defensive characteristics. Beta measures price volatility relative to the Nifty 50. Lower beta stocks provide stability during uncertain market conditions. Consider beta alongside your risk tolerance and portfolio diversification strategy.
What is the 52-week high and low for ASTRAZEN?
ASTRAZEN has a 52-week high of ₹N/A and low of ₹N/A. Currently trading at ₹9222.50, the stock is within its annual trading range. Trading near highs indicates strong momentum but limited upside potential.
What are the key risks associated with investing in ASTRAZEN?
Key risks for ASTRAZEN include: Market volatility (Beta: N/A), financial leverage (Debt-to-Equity: 0.05), and operational challenges. The stock has a Fundamental Score of 75.4/100, indicating strong fundamentals with lower risk profile. Sector-specific risks in Pharmaceuticals & Biotechnology include regulatory changes, economic cycles, and competitive pressures. Consider your risk tolerance, investment horizon, and portfolio diversification before investing. Past performance doesn't guarantee future results.
What is ASTRAZEN's operating profit margin and how has it trended?
ASTRAZEN has a 5-year average Operating Profit Margin (OPM) of 14.65%, which is good and shows decent operational efficiency. Operating Profit Margin shows operational efficiency by measuring operating profit as a percentage of revenue. Monitor margin trends to assess management's ability to control costs and improve efficiency. Compare with industry peers to understand relative performance.
How is ASTRAZEN's quarterly performance in terms of sales and profit growth?
ASTRAZEN's recent quarterly performance shows YoY Sales Growth of 35.81% and YoY Profit Growth of 60.14%. This strong double-digit growth indicates excellent business momentum and management execution. Sales growth shows market demand while profit growth reveals operational efficiency and margin management.
What is the FII and DII holding pattern in ASTRAZEN?
ASTRAZEN has FII holding of 3.03% and DII holding of 4.55%, totaling 7.58% institutional ownership. This institutional participation level shows the confidence of professional money managers. Monitor quarterly changes in institutional holdings for investment flow trends and sentiment.